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A female was born at 36+5 weeks of gestation with a birth weight of 2,120 g. Apgar score was 7 at 
1 minute and 9 at 5 minutes. Shortly after birth, tachypnea, chest retraction, and a severe build-
up of oral secretions were noted. Her blood type was A+ and initial hemoglobin was 17.5 g/dl. 
Her mother was A+ blood type. Ampicillin/Sulbactam and gentamicin were started empirically. 
At 8th day of admission, laboratory results showed hemolytic anemia. Exchange transfusion 
was performed along with intravenous immunoglobulin and hydrocortisone. After 2 days, the 
patient’s clinical and laboratory conditions improved. Column hemagglutination assay revealed 
that the patient’s hemolysis was due to ampicillin/sulbactam. 
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Introduction
Drug-induced immune hemolytic anemia (DIIHA) is rare, with the incidence estimated to 
be approximately one in 1 million, although exact data are lacking.1 The incidences of drug-
induced immune thrombocytopenia and neutropenia are approximately 10-18 and 2-15 cases 
per million, respectively.2 
Limited data are available about DIIHA in a premature infant, whose immune system is 
immature and not fully functional. Here, we report the case of a preterm infant who presented 
with severe anemia and jaundice one to two days following prophylactic administration of 
ampicillin/sulbactam after a tracheoesophageal fistula operation. DIIHA was diagnosed by a 
column hemagglutination assay and the infant was treated by exchange transfusion.  
Case
A female second born twin was born at 36+5 weeks of gestation with a birth weight of 
2,120 g by Cesarean section at a local clinic. The patient’s Apgar score was 7 at 1 minute 
and 9 at 5 minutes. Shortly after birth, tachypnea, chest retraction, and a severe build-up of 
oral secretions were noted. An orogastric tube could not be advanced, and the initial chest 
radiograph revealed that the orogastric tube was coiled, suggesting a Tracheoesophageal fistula 
with esophageal atresia. The patient was then referred to our neonatal intensive care unit for 
surgery. Her blood type was A+ and initial hemoglobin was 17.5 g/dl. TORCH and Tandem 
mass screening tests were within normal limits. Her mother was a 32-year-old gravida 1 para 
0 woman, with preterm labor, who had A+ blood type and had received dexamethasone two 
times, but no antibiotics, prior to delivery.   
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Ampicillin/sulbactam (Ubacillin®, 120 mg/kg/day, intravenously) 
and gentamicin (8 mg/kg/day, intravenously) were started empirically 
and prophylactically in preparation for surgery on the first day of 
life. Although the operation to repair the fistula (Tracheoesopha-
geal fistulization) was successful, the patient’s hemoglobin level 
decreased and indirect/direct hyperbilirubinemia increased, 
first gradually and then dramatically (Hemoglobin: 18.2, 16.9 
and 10.6 g/dL at 1st, 2nd and 5th day of life; Total bilirubin: 7.7 
and 24 mg/dL at 2nd and 5th day of life). However, the results 
of direct/indirect Coombs tests were negative. Despite packed 
red blood cell (RBC) transfusion and intensive phototherapy, 
the patient’s condition continued to worsen and seizures were 
observed at 6th day of life.
At that time, the patient’s C-reactive protein (CRP) levels 
increased to 3.6 mg/dL (Normal range, <0.3). The antibiotics 
were then changed to vancomycin (20 mg/kg/day) and amikacin 
(13 mg/kg/day). Other laboratory studies revealed the following: 
hemoglobin 5 g/dL, hematocrit 14.3%, MCV/MCH/MCHC 94.7 
fl/33.1 pg/35.0%, reticulocyte count 30.71%, total bilirubin 40.5 
mg/dL, direct bilirubin 22.4 mg/dL, increased urobilinogen, urinary 
occult blood 3+, urine RBC 1-4/HPF, and negative direct/indirect 
Coombs tests. Peripheral blood smear showed anisocytosis 2+ 
and poikilocytosis 2+. The patient also demonstrated frequent 
oxygen desaturation and bradycardia that required mechanical 
ventilation. The seizure was probably due to kernicterus or 
hypoxia induced by acute decrease of hemoglobin, but the 
exchange transfusion was delayed because the patient showed 
melena. On the eight day of life, after improvement of melena, 
it was decided to perform an exchange transfusion (using twice 
the baby’s blood volume) with a mixture of O+ RBCs and AB+ 
fresh frozen plasma along with intravenous immunoglobulin 
(IVIG, 500 mg/kg/day, 2 day course) and Hydrocortisone(Solu-
cortef®, 1 mg/kg, 2 day course). On the ninth day, a further RBC 
transfusion was given along with testing for glucose-6 phosphate 
dehydrogenase (G-6-PD) deficiency, which was negative.
From the tenth day of life, 2 days following the exchange trans-
fusion, the patient’s clinical and laboratory conditions improved. 
She did not require further transfusion and was discharged from the 
hospital on the 25th day of life. Before discharge, we performed 
brain MRI and it showed signs of acute kernicterus as we expected. 
A brief clinical course, as well as the patient’s hemoglobin and 
bilirubin levels, are presented in Fig. 1.       
At discharge, her hematologic and bilirubin values were: 
hemoglobin, 12.6 g/dL; hematocrit, 36.9%; reticulocyte, 2.5%; 
total bilirubin, 2.8 mg/dL; and direct bilirubin, 2.3 mg/dL. The 
patient’s clinical and laboratory stabilization was continued with 
close follow-up in the outpatient setting. 
To clarify the mechanism of her aggressive hemolysis, a column 
Fig. 1. The pattern of hemoglobin and bilirubin levels according to antibiotics 
and other treatments. Abbreviations: Amp, ampicillin; Hb, hemoglobin (g/dL); TB, 
total bilirubin (mg/dL); DB, direct bilirubin (mg/dL); Reti, reticulocyte (%); IVIG, 
intravenous immunoglobulin; RBC, packed red blood cell transfusion; ExTF, exchange 
transfusion.
Roh JH, et al.  Ampicillin/Sulbactam-induced hemolytic Anemia
192 http://dx.doi.org/10.14734/PN.2016.27.3.190 www.e-kjp.org
Perinatology
hemagglutination assay (Ortho Diagnostics, Raritan, NJ, USA) was 
performed twice, using the patient’s RBC and serum collected 
on the 15th and 50th days of life. The patient’s sera were not 
reactive against untreated RBCs in the presence of vancomycin 
and ampicillin/sulbactam. The patient’s serum obtained on the 
15th day of age was strongly reactive with ampicillin/sulbactam-
coated RBCs, which were obtained on the 50th day of life and 
treated with ampicillin/sulbactam for 30 minutes. However, this 
positive control serum was not reactive with ampicillin/sulbactam-
coated RBCs from other donors (Fig. 2). Strangely, reactivity 
was weakly positive between ampicillin/sulbactam-coated RBCs 
from the patient (15th day of life) and the patient’s serum (15th 
day of life) (+1). Moreover, ampicillin/sulbactam-coated RBCs 
(50th day of life) did not react with the patient’s serum from the 
50th day of life. RBCs treated with vancomycin were nonreactive 
after incubation with the patient’s sera. In conclusion, these 
results suggested that our patient’s hemolysis was induced by 
ampicillin/sulbactam. 
Discussion
DIIHA is a rare and serious adverse reaction that may result 
from drug administration.2-7 The most common drugs associated 
with DIIHA and the potential mechanisms thought to be involved 
have changed over the last few decades.2 Both ampicillin and 
sulbactam contained in ampicillin/sulbactam accounted for 1.3 
to 23% of reported cases of DIIHA.2 
Suggested mechanisms involved in drug-induced immune 
hemolytic anemia are summarized as follows; (1) Drug-dependent 
antibodies will only react in vitro in the presence of the drug.2 Most 
penicillins and cephalosporins are capable of covalently bonding 
to proteins on RBC membranes, providing drug-coated RBCs for 
detection of certain drug antibodies in vitro.2,8 (2) The majority 
of drugs that cause acute, severe, intravascular hemolysis, and 
sometimes disseminated intravascular coagulation and death, seem 
to be involved in the so-called immune complex mechanism.9 (3) 
Drug-independent antibodies can be detected in vitro without 
adding any drug; thus, in vitro and in vivo characteristics are 
identical to those of RBC autoantibodies that are antibodies to 
the carrier protein alone.8 (4) Recently, Garratty et al. reported 
a “unifying hypothesis” for DIIHA that provided a model for all 
three types of drug antibodies.1,2 If drug is bound to protein on 
RBCs, three populations of antibodies might be found; hapten 
(drug), combination of hapten plus carrier protein epitopes, 
and carrier protein.2 (5) Another new concept, non-immune 
protein adsorption (NIPA), has drawn increasing interest.10,11 
Some drugs (β-lactamase inhibitors; sulbactam, clavulanate, and 
tazobactam) appear to be capable of modifying RBC membrane 
so that proteins (IgG, complement, albumin, and fibrinogen, 
among others) become non-immunologically adsorbed onto 
the RBC membrane.2,10,11
In our case, hemolytic anemia developed after the use of 
ampicillin/sulbactam. Moreover, when ampicillin/sulbactam 
administration was discontinued and exchange transfusion was 
performed, the hemolytic anemia soon resolved. Eventually, 
this peculiar remission after discontinuing ampicillin/sulbactam, 
and ampicillin/sulbactam - coated RBC reactivity, supported 
the diagnosis of drug - induced hemolytic anemia. The weak 
positive result on the 15th day of life, as detected by a column 
hemagglutination assay, may have been due to dilution of the 
patient’s RBCs by packed RBCs used in the exchange transfusion. 
Fig. 2. The detection of RBC antibody in patient’s serum. The patient’s 
serum was obtained on the 15th day of age and the patient’s RBC 
on the 50th day of age respectively. The serum was reactive with the 
patient’s RBC coated with ampicillin/sulbactam.
A(negative)=patient’s RBC+patient’s serum+ampicillin/sulbactam; B 
(negative)=type O blood donor 1’s RBC+patient’s serum+ampicillin/
sulbactam; C (negative)=type O blood donor 2’s RBC+patient’s 
serum+ampicillin/sulbactam; D (4+ positive) =ampicillin/sulbactam-
coated patient’s RBC+patient’s serum; E (negative)=ampicillin/
sulbactam-coated type O blood donor 1’s RBC+patient’s serum; F 





The non-reactivity of the patient’s serum obtained from the 50th 
day of life may be secondary to the short half-life and deficit of 
the absolute amount of IgG, and the concentration of IgG that 
falls postnatally in preterm infants.
Among above several possible mechanisms of hemolysis, drug 
(hapten) adsorption or drug adsorption type in “unifying mechanism” 
in relation to ampicillin is considered a possible mechanism in the 
current case. In our column hemagglutination assay, we found 
negative reactivity with simultaneous mixture of the patient’s 
and donor RBCs, serum, and the drug, which suggested that 
an immune complex mechanism could be excluded. However, 
we did not obtain laboratory confirmation of such an effect due 
to sulbactam (β-lactamase inhibitor), which is a component of 
ampicillin/sulbactam and might induce non-immune protein 
adsorption (NIPA). Hemolysis induced by β-lactamase inhibitor-
containing drugs has been proven to have a high incidence of 
a positive direct Coombs test.10,11
In drug-induced immune hemolysis, positivity of the direct 
Coombs test is usually high.12,13 Weaker positive direct Coombs 
tests are seen when the patient is off the drug for some time. 
The negative results in our patient may have been due to a 
weakening effect of the transfused blood product, IVIG, or due 
to late sampling time after discontinuation of the ampicillin/
sulbactam, at which time the drug-coated RBCs were mostly 
destroyed. Similarly, Arndt et al. reported that the strength of 
the direct Coombs test varied from 4+ to weak+ in second- and 
third-generation cephalosporin associated immune hemolytic 
anemia.14
In summary, we conclude that the severe anemia and jaundice in 
this patient were due to ampicillin/sulbactam-induced hemolysis, 
based on the fact that the patient’s serum was strongly reactive 
with the patient’s own RBCs coated with ampicillin/sulbactam. 
This diagnosis was confirmed by a column hemagglutination assay.
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